CMS Cuts 2027 Lab Rates, Sending Labcorp and Quest Lower
LH sits 25% above its 52-week low of $244.52.
Summary
CMS has cut 2027 reimbursement rates for laboratory services, directly pressuring Labcorp's core testing revenue. Shares are falling alongside Quest Diagnostics as the market reprices the impact. This is a regulatory headwind that could compress margins if volume growth doesn't offset lower per-test payments. Labcorp's recent guidance and long-term targets did not account for this cut, so estimates may need revision. Watch for company commentary on the magnitude of the rate reduction and any mitigation plans.
At the time of this announcement, LH was trading at $305.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $244.52 to $341.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.